Rong Tian1, Tao Liu2, Li Qiao1, Mei Gao1, Jing Li3. 1. Department of Dermatology, General Hospital of The Air Force Beijing, China. 2. Department of Dermatology, Tangdu Hospital, The Fourth Military Medical University Xi'an, China. 3. Department of Burns and Plastic Surgery, Tangdu Hospital, The Fourth Military Medical University Xi'an, China.
Abstract
BACKGROUND AND PURPOSE: MicroRNA-206 (miR-206) acts as a tumor suppressor in melanoma cell lines. However, its clinical significance remains unclear. The aim of this study was to detect the serum level of miR-206 in patients with melanoma and to determine the feasibility of using it as a noninvasive prognostic biomarker. METHODS: Expression levels of miR-206 in serum samples from 60 patients with melanoma and 30 healthy controls were detected by real-time quantitative polymerase chain reaction (q-PCR). RESULTS: Expression levels of miR-206 in serum samples from patients with melanoma were significantly lower than those in healthy controls (P<0.001). In addition, low serum miR-206 level was more frequently observed in patients with two or more metastatic sites (P=0.02). Its serum level was also significantly associated with the response to treatment (P=0.01). Moreover, melanoma patients with low serum miR-206 levels had higher clinical stage than those with high serum miR-206 levels (P<0.001). Furthermore, melanoma patients with low serum miR-206 level had a dramatically shorter 5-year overall and disease-free survival than those with high serum miR-206 level (both P=0.001). Multivariate analysis also identified the serum miR-206 level as an independent marker for both 5-year overall and disease-free survivals (both P=0.01) in patients with melanoma. CONCLUSIONS: Our results offer the convincing evidence that miR-206 may be implicated in aggressive progression of melanoma. More importantly, the serum level of miR-206 may be a noninvasive prognostic biomarker for the patients with melanoma.
BACKGROUND AND PURPOSE:MicroRNA-206 (miR-206) acts as a tumor suppressor in melanoma cell lines. However, its clinical significance remains unclear. The aim of this study was to detect the serum level of miR-206 in patients with melanoma and to determine the feasibility of using it as a noninvasive prognostic biomarker. METHODS: Expression levels of miR-206 in serum samples from 60 patients with melanoma and 30 healthy controls were detected by real-time quantitative polymerase chain reaction (q-PCR). RESULTS: Expression levels of miR-206 in serum samples from patients with melanoma were significantly lower than those in healthy controls (P<0.001). In addition, low serum miR-206 level was more frequently observed in patients with two or more metastatic sites (P=0.02). Its serum level was also significantly associated with the response to treatment (P=0.01). Moreover, melanomapatients with low serum miR-206 levels had higher clinical stage than those with high serum miR-206 levels (P<0.001). Furthermore, melanomapatients with low serum miR-206 level had a dramatically shorter 5-year overall and disease-free survival than those with high serum miR-206 level (both P=0.001). Multivariate analysis also identified the serum miR-206 level as an independent marker for both 5-year overall and disease-free survivals (both P=0.01) in patients with melanoma. CONCLUSIONS: Our results offer the convincing evidence that miR-206 may be implicated in aggressive progression of melanoma. More importantly, the serum level of miR-206 may be a noninvasive prognostic biomarker for the patients with melanoma.
Authors: Dóra Mihály; Gergő Papp; Zsolt Mervai; Andrea Reszegi; Péter Tátrai; Gábor Szalóki; Johanna Sápi; Zoltán Sápi Journal: Exp Biol Med (Maywood) Date: 2018-08-15
Authors: Nicholas Latchana; Kelly Regan; J Harrison Howard; Jennifer H Aldrink; Mark A Ranalli; Sara B Peters; Xiaoli Zhang; Alejandro Gru; Philip R O Payne; Lorena P Suarez-Kelly; William E Carson Journal: J Surg Res Date: 2016-07-04 Impact factor: 2.192